Protagonist Therapeutics Inc (NASDAQ: PTGX)’s stock price has decreased by -3.17 compared to its previous closing price of 42.57. However, the company has seen a -11.35% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-03-25 that The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
Protagonist Therapeutics Inc (NASDAQ: PTGX) has a price-to-earnings ratio that is above its average at 9.80x. The stock has a 36-month beta value of 2.66. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PTGX is 57.88M, and at present, short sellers hold a 8.13% of that float. On April 10, 2025, the average trading volume of PTGX was 1.07M shares.
PTGX’s Market Performance
The stock of Protagonist Therapeutics Inc (PTGX) has seen a -11.35% decrease in the past week, with a -28.50% drop in the past month, and a 9.57% gain in the past quarter. The volatility ratio for the week is 7.77%, and the volatility levels for the past 30 days are at 5.25% for PTGX. The simple moving average for the past 20 days is -15.61% for PTGX’s stock, with a -1.56% simple moving average for the past 200 days.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Goldman repeating the rating for PTGX by listing it as a “Neutral.” The predicted price for PTGX in the upcoming period, according to Goldman is $47 based on the research report published on December 06, 2024 of the previous year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $62. The rating they have provided for PTGX stocks is “Outperform” according to the report published on December 06th, 2024.
Wedbush gave a rating of “Outperform” to PTGX, setting the target price at $58 in the report published on November 05th of the previous year.
PTGX Trading at -5.87% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.98% of loss for the given period.
Volatility was left at 5.25%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares sank -24.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.35% upper at present.
During the last 5 trading sessions, PTGX fell by -10.97%, which changed the moving average for the period of 200-days by +29.33% in comparison to the 20-day moving average, which settled at $48.85. In addition, Protagonist Therapeutics Inc saw 6.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from Waddill William D., who sale 4,000 shares at the price of $54.25 back on Mar 17 ’25. After this action, Waddill William D. now owns 13,130 shares of Protagonist Therapeutics Inc, valued at $217,000 using the latest closing price.
WILLIAM D WADDILL, the Director of Protagonist Therapeutics Inc, proposed sale 4,000 shares at $54.78 during a trade that took place back on Mar 17 ’25, which means that WILLIAM D WADDILL is holding shares at $219,120 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.58 for the present operating margin
- 1.0 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.63. The total capital return value is set at 0.36. Equity return is now at value 54.39, with 49.81 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 16.95.
Currently, EBITDA for the company is 252.84 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 5.59. The receivables turnover for the company is 2.58for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.48.
Conclusion
To sum up, Protagonist Therapeutics Inc (PTGX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
